Publications by authors named "Carlos Escobar-Cervantes"
Background: The optimal radiofrequency application (RFa) parameters for safe and durable pulmonary vein isolation (PVI) are debated. High-power short-duration (HPSD) has been used as an alternative to conventional power delivery (CPD).
Objectives: This study sought to compare HPSD 70 W/9-10 s (HPSD-70) with CPD 25-40 W in patients undergoing PVI.
Prevalence Rates of Abdominal Obesity, High Waist-to-Height Ratio and Excess Adiposity, and Their Associated Cardio-Kidney-Metabolic Factors: SIMETAP-AO Study.
Nutrients
November 2024
Article Synopsis
- - The study examined the prevalence of abdominal obesity (AO), high waist-to-height ratio (WtHR), and excess adiposity (EA) in a sample of 6,588 adults aged 18 to 102 years and their connections to cardiovascular-kidney-metabolic (CKM) syndrome factors.
- - Results showed that 39.6% of participants had AO, 30.6% had high-WtHR, and 65.6% had EA, with higher rates observed in older individuals; key health issues like hypertension and diabetes were linked to these conditions.
- - Findings indicate that a significant portion of the adult population experiences EA and AO, highlighting an independent association between these obesity metrics and other CKM syndrome factors
Article Synopsis
- Atrial fibrillation (AF) is the most common arrhythmia and a leading cause of hospital admissions due to strokes, prompting the SIMETAP research project to investigate its prevalence and related cardiovascular-kidney-metabolic (CKM) factors.
- A study involving 6,588 adults found that AF affects 2.9% of the overall adult population, with rates rising to 6.1% for those 50 and older, and 12.9% for those 70 and older, showing no significant sex differences.
- Key CKM factors associated with AF include heart failure, hypertension, chronic kidney disease, prior stroke, and low HDL-cholesterol, with a staggering 92.4% of
Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study.
J Clin Med
August 2024
Scientific societies disagree on serum uric acid (SUA) thresholds for the diagnosis of hyperuricaemia (HU) according to epidemiological or physiochemical criteria (SUA ≥ 7.0 mg/dL for men and ≥6.0 mg/dL for women [HU-7/6]; SUA ≥ 7.
View Article and Find Full Text PDFSGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
Lancet Diabetes Endocrinol
August 2024
Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study.
Front Cardiovasc Med
December 2023
Objectives: To determine the clinical profile, according to the history of hypertension, the risk of developing hypertension, current antihypertensive treatment and BP control rates in patients with hypertension from the IBERICAN cohort.
Methods: IBERICAN is an ongoing prospective cohort study, whose primary objective is to determine the frequency, incidence, and distribution of CVRF in the adult Spanish population seen in primary care settings. This analysis shows the baseline clinical characteristics of patients with hypertension.
Introduction: In addition to an increased risk of thromboembolic complications, patients with atrial fibrillation (AF) are at risk for vascular events. Consequently, complete vascular protection is warranted in these patients.
Areas Covered: A narrative search was conducted on PubMed (MEDLINE), using the MeSH terms [Rivaroxaban] + [Atrial fibrillation] + [Cardiovascular] + [Vascular] + [Treatment].
Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study.
Medicina (Kaunas)
October 2023
: Arterial hypertension (HTN) is the leading preventable cause of atherosclerotic cardiovascular diseases (ASCVD) and death from all causes. This study aimed to determine the prevalence rates of HTN diagnosed according to the threshold diagnostic criteria 130/80 mmHg and 140/90 mmHg, to compare blood pressure (BP) control, and to evaluate their associations with cardiovascular diseases and cardiometabolic and renal risk factors. : This was a cross-sectional observational study conducted in primary care with a population-based random sample: 6588 people aged 18.
View Article and Find Full Text PDFArticle Synopsis
- * Patients with AF have a residual stroke risk of 1-2% annually even with anticoagulation therapy and may experience cognitive impairment through non-stroke-related pathways.
- * Both AF and atherosclerotic vascular disease are interconnected, indicating that patients with AF may also be at higher risk for kidney disease, requiring a holistic treatment strategy that encompasses vascular protection beyond medication.
Background: Guidelines recommend pharmacological treatment for systolic blood pressure (SBP) of 130 to 139 mm Hg in secondary prevention. However, uncertainty persists in primary prevention in low cardiovascular risk patients (CVR).
Methods: Cohort study representative of the general population of Albacete/Southeast Spain.
Introduction And Objectives: Heart failure (HF) is a major health problem that causes high mortality and hospitalization rates. This study aims to determine the HF prevalence rates in populations aged both ≥18 years and ≥50 years and to assess its association with cardiovascular diseases and chronic kidney disease.
Methods: A cross-sectional observational study was conducted in a primary care setting, with a population-based random sample of 6588 people aged 18.
To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with reduced ejection fraction in clinical practice in Spain. This multicenter cohort study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were estimated based on results from the DAPA-HF trial.
View Article and Find Full Text PDFArticle Synopsis
- A multicenter study in Spain examined the potential benefits of dapagliflozin for patients with heart failure (HF) with mildly reduced or preserved ejection fraction.
- Out of 4049 patients over 50 years old, 80.8% met the criteria for dapagliflozin treatment, with significant rates of rehospitalization (22.2%) and mortality (21.6%) within a year after discharge.
- The use of dapagliflozin is projected to reduce the absolute risk of mortality by 1.3% and HF readmissions by 5.1%, indicating a potential to lessen the burden of HF in these patients.
To determine the projected benefits of dapagliflozin after an acute heart failure (HF) event in Spain. A multicenter and prospective study that included subjects aged 50 years or older consecutively admitted with HF to internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were calculated pooled analysis of the DAPA-HF and DELIVER trials.
View Article and Find Full Text PDFArticle Synopsis
- * Early intervention is crucial, focusing on lifestyle changes and specific medications to manage both metabolic and cardiovascular risks effectively.
- * A consensus among various healthcare specialists emphasizes a comprehensive strategy for T2DM management, including patient education, revising medication regimens, and promoting the use of certain drugs known to enhance cardiovascular protection.
Background And Aims: We aimed to understand the impact of physicians' perception about LDL-cholesterol (LDLc) control on the management of patients with dyslipidemia in Spain.
Methods: We performed a cross-sectional and multicenter study, in which 435 healthcare professionals participated in face-to-face meetings, collecting qualitative and quantitative information related to hypercholesterolemia management. Additionally, aggregated anonymized data of the last 10 patients with hypercholesterolemia attended by each physician were collected.
Article Synopsis
- The study aimed to assess how well dyslipidaemia is controlled and the types of lipid-lowering therapies used among patients at high and very high cardiovascular risk across different regions in Spain.
- Data was gathered from 145 health areas involving 435 physicians, resulting in a total of 4010 patients being analyzed for their cardiovascular risk and therapy received.
- Findings revealed that although patient distribution was similar across regions, significant variances existed in achieving cholesterol targets and in the types of therapies prescribed, highlighting regional disparities in cardiovascular prevention strategies.
Objective: We aimed to test the non-inferiority of oral versus intravenous hydration in the incidence of contrast-associated acute kidney injury (CA-AKI) in elderly outpatients undergoing a contrast-enhanced computed tomography (CE-CT) scan.
Methods: PNIC-Na (NCT03476460) is a phase-2, single-center, randomized, open-label, non-inferiority trial. We included outpatients undergoing a CE-CT scan, >65 years having at least one risk factor for CA-AKI, such as diabetes, heart failure, or an estimated glomerular filtration rate (eGFR) of 30-59 mL/min/1.
Introduction: Worsening heart failure (HF) is associated with a high risk of death and HF hospitalization.
Areas Covered: A systematic search was conducted on PubMed (MEDLINE), using the MeSH terms [Heart failure] + [Worsening] + [Treatment] + [Vulnerable period] up to February 2023. Original data from clinical trials, and observational studies were critically analyzed.
The pathophysiology of heart failure with reduced ejection fraction (HFrEF) is a complex process in which a number of neurohormonal systems are involved. Targeting only some of these systems, but not all, translates into a partial benefit of HF treatment. The nitric oxide-soluble guanylate cyclase (sGC)-cGMP pathway is impaired in HF, leading to cardiac, vascular and renal disturbances.
View Article and Find Full Text PDFMulticenter prospective comparison of conventional and high-power short duration radiofrequency application for pulmonary vein isolation: the high-power short-duration radiofrequency application for faster and safer pulmonary vein ablation (POWER FAST III) trial.
J Interv Card Electrophysiol
November 2023
Article Synopsis
- A multicenter clinical trial called POWER FAST III is set to compare high-power short-duration (HPSD) radiofrequency ablation with standard techniques for treating atrial fibrillation (AF), aiming to reduce procedure time without sacrificing safety or effectiveness.
- The study involves two groups: one using higher power settings (70 W and 9-10 seconds) and another using lower power (25-40 W), measuring atrial arrhythmia recurrence and the risk of esophageal damage.
- Results are expected to potentially validate the HPSD approach, influencing future clinical practices for AF ablation procedures.
Article Synopsis
- The study investigates the relationship between achieved low-density lipoprotein cholesterol (LDL-C) levels and healthcare costs in patients who underwent lipid-lowering therapy after a recent myocardial infarction (heart attack) in Spain.
- Out of 6025 patients analyzed, only 11% met the LDL-C goals set by 2016 guidelines, and a mere 1% reached the more stringent goals of the 2019 guidelines.
- Achieving lower LDL-C levels was linked to significantly reduced healthcare resource use and costs, suggesting that more intensive lipid-lowering treatments could be economically and clinically beneficial.
Aims: A Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with non-valvular atrial fibrillation in Spain.
Methods: All inputs were derived from real-world studies: baseline patient characteristics, clinical event rates, as well as persistence rates for the vitamin K antagonist treatment option.
Introduction And Objectives: The treatment of dyslipidemia exhibits wide variability in clinical practice and important limitations that make lipid-lowering goals more difficult to attain. Getting to know the management of these patients in clinical practice is key to understand the existing barriers and to define actions that contribute to achieving the therapeutic goals from the most recent Clinical Practice Guidelines.
Methods: Observatory where the information gathered is based on routine clinical practice and the experience from the healthcare professionals involved in the treatment of dyslipidemia in Spain.
Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018.
Rev Esp Cardiol (Engl Ed)
June 2022
Article Synopsis
- Atrial fibrillation (AF) has become more common, increasing the risk of strokes, but recent studies indicate that the use of direct oral anticoagulants (DOACs) may be reducing stroke rates related to AF in Spain.
- The study used data from the Spanish Ministry of Health to analyze the relationship between DOAC use and AF-related ischemic strokes in patients aged 65 and older, using statistical models for analysis.
- Results showed that before DOACs were widely used, the incidence of AF-related strokes rose, but after their introduction, rates stabilized or slightly decreased, indicating that higher DOAC uptake may positively impact health outcomes for AF patients.